𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas

✍ Scribed by Julia Reifenberger; Christiane B. Knobbe; Astrid A. Sterzinger; Britta Blaschke; Klaus W. Schulte; Thomas Ruzicka; Guido Reifenberger


Publisher
John Wiley and Sons
Year
2004
Tongue
French
Weight
857 KB
Volume
109
Category
Article
ISSN
0020-7136

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Ras signaling is important for the intracellular transduction of mitogenic stimuli from activated growth factor receptors. We have investigated 37 sporadic malignant melanomas (15 primary cutaneous melanomas and 22 melanoma metastases) and 6 melanoma cell lines for mutations in the 3 Ras genes NRAS, KRAS and HRAS. All tumors and cell lines were additionally analyzed for mutation and expression of BRAF, which encodes a Ras‐regulated serine/threonine kinase with oncogenic properties, as well as for expression of RASSF1A, which encodes a Ras‐binding protein with tumor suppressor properties. Mutational analyses identified somatic NRAS mutations in 2 primary melanomas, 4 melanoma metastases and 2 cell lines. One melanoma metastasis showed a somatic KRAS mutation whereas HRAS mutations were not detected. Eight primary melanomas, 6 melanoma metastases and 4 melanoma cell lines carried BRAF mutations affecting the known hot‐spot codon 599. None of the tumors or cell lines with BRAF mutation demonstrated NRAS or KRAS mutations. Real‐time reverse transcription‐PCR showed that 8 melanomas (3 primary tumors, 5 melanoma metastases) had reduced RASSF1A transcript levels of ≤50% relative to benign melanocytic nevi and normal skin. Three melanoma cell lines lacked detectable RASSF1A transcripts. The RASSF1A gene promoter was hypermethylated in these 3 cell lines as well as in 6 of 8 melanomas with reduced RASSF1A mRNA levels. Treatment of the cell lines with 5‐aza‐2′‐deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re‐expression of RASSF1A transcripts. Most tumors and all cell lines with RASSF1A promoter methylation additionally carried BRAF or NRAS mutations, suggesting a synergistic effect of these aberrations on melanoma growth. Taken together, 57% of the investigated melanomas and 100% of the melanoma cell lines carried mutations in either NRAS, KRAS or BRAF. In addition, 22% of the melanomas and 50% of the cell lines showed reduced RASSF1A transcript levels. Thus, alterations of Ras pathway genes are of paramount importance in the pathogenesis of sporadic melanomas. © 2004 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Frequent promoter hypermethylation of Wn
✍ Silke Götze; Marietta Wolter; Guido Reifenberger; Oliver Müller; Sonja Sievers 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 French ⚖ 656 KB

## Abstract Aberrant activation of wingless (Wnt) signaling is involved in the pathogenesis of various cancers. Recent studies suggested a role of Wnt signaling in gliomas, the most common primary brain tumors. We investigated 70 gliomas of different malignancy grades for promoter hypermethylation

Altered expressions of HOX genes in huma
✍ Kazuhiko Maeda; Jun-Ichi Hamada; Yoko Takahashi; Mitsuhiro Tada; Yuhei Yamamoto; 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 French ⚖ 207 KB

## Abstract __HOX__ genes act as master genes to control morphogenesis. In human, HOX genes form 4 clusters composing 9 to 11 __HOX__ genes (39 genes in total) on different chromosomes. We hypothesized that aberrant expression of __HOX__ genes was associated with development and subsequent progress

Molecular genetic analysis of malignant
✍ Julia Reifenberger; Christiane B. Knobbe; Marietta Wolter; Britta Blaschke; Klau 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 French ⚖ 952 KB

## Abstract Aberrant activation of the Wnt signaling pathway has been reported in different human tumor types, including malignant melanomas. We investigated 37 malignant melanomas (15 primary tumors and 22 metastases) for alterations of 4 genes encoding members of this pathway, __i.e.,__ __CTNNB1_

Silencing of tissue factor pathway inhib
✍ Yoshimasa Nobeyama; Eriko Okochi-Takada; Junichi Furuta; Yohei Miyagi; Kanako Ki 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 French ⚖ 462 KB

## Abstract To identify tumor‐suppressor genes inactivated by aberrant methylation of promoter CpG islands (CGIs) in human malignant melanomas, genes upregulated by treatment of cells with a demethylating agent, 5‐aza‐2′‐deoxycytidine (5‐aza‐dC), were searched for using oligonucleotide microarrays

Ornithine decarboxylase gene expression
✍ Robert A. R. Hurta; Jim A. Wright 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 976 KB

We have tested the hypothesis that H-ras transformed cells contain alterations in signal pathways important in controlling the expression of ornithine decarboxylase (ODC), the highly regulated rate-limiting activity in the biosynthesis of poly-